Avsnitt
-
In part two of this series, Dr. Halley Alexander discusses seizure types, epilepsy types, and the etiology of epilepsy. Show citations: Beniczky S, Trinka E, Wirrell E, et al. Updated classification of epileptic seizures: Position paper of the International League Against Epilepsy. Epilepsia. 2025;66(6):1804-1823. doi:10.1111/epi.18338
Beniczky S, Trinka E, Wirrell E, et al. A practical guide to the updated seizure classification 2025. Epileptic Disord. 2025;27(6):1087-1104. doi:10.1002/epd2.70110
-
Dr. Greg Cooper and Dr. Elisabeth Kurpershoek discuss how clinicians communicate uncertainty during Parkinson's disease diagnosis and how this impacts patient trust and understanding.
Show citation:
Hillen MA, Kurpershoek E, Huisman MHB, et al. Clinician Communication About Uncertainty During Parkinson Disease Diagnostic Consultations. Neurol Clin Pract. 2026;16(3):e200613. doi:10.1212/CPJ.0000000000200613
-
Saknas det avsnitt?
-
Dr. Katie Krulisky and Dr. Marcus Pinto discuss the diagnosis and management of hereditary ATTR amyloidosis.
Show citation:
Panrudkevich AH, Jones FJS, Shouman K, et al. Sensitivity of Nerve and Skin Biopsy and Fat Aspirate for Amyloid in Symptomatic Hereditary ATTR Amyloidosis With Peripheral Neuropathy. Neurology. 2026;106(11):e218033. doi:10.1212/WNL.0000000000218033
-
In part one of this series, Dr. Halley Alexander explores epilepsy diagnosis.
Previously posted Neurology Minute episodes related to epilepsy syndromes and their diagnosis.
Show citation:
Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475-482. doi:10.1111/epi.12550
-
Dr. Aaron Zelikovich discusses the frequency of LRP4-IgG in patients with suspected MG using different cell-based assay protocols.
Show citation:
Vacchiano V, Milano DC, Ricciardiello F, et al. Low Prevalence and Inconsistency of LRP4-IgG Detection in Suspected Myasthenia Gravis: A Multicenter CBA Comparison Neurology: Neuroimmunology & Neuroinflammation. 2026;13(3). doi:10.1212/NXI.0000000000200554
-
In part two of this series, Dr. Andy Southerland and Dr. Seemant Chaturvedi discuss the use of dual antiplatelet therapy with intravenous thrombolysis in patients with acute ischaemic stroke.
Read more about the TAPIS trial.
-
In part one of this series, Dr. Andy Southerland and Dr. Seemant Chaturvedi discuss insights from the LATE-MT trial that was presented at the 2026 European Stroke Organization Conference.
Read more about LATE-MT trial.
-
Dr. Shuvro Roy and Dr. Michael Levy discuss satralizumab for treating relapsing MOGAD, current management challenges, and the encouraging results of this new therapy.
Read more about this abstract.
-
In part three of this series, Dr. Aaron Zelikovich discusses the clinical outcomes seen during and after the acute infection and how these findings can guide physicians in counseling their patients.
Show citation:
Solomon T, Hooper C, Easton A, et al. Safety and efficacy of adjunct dexamethasone in adults with herpes simplex virus encephalitis in the UK (DexEnceph): a multicentre, observer-blind, randomised, phase 3, controlled trial. Lancet Neurol. 2026;25(2):136-146. doi:10.1016/S1474-4422(25)00454-5
-
In part two of this series, Dr. Jeff Ratliff and Dr. Gabriela Figueiredo Pucci discuss the lessons and experiences that happen in neurology-related social media interaction.
Show citation:
Pucci GF, Gheihman G, Albin CSW. Education Research: A Qualitative Analysis of the Role of Social Media in Neurology Trainees' Professional Identity Formation. Neurol Educ. 2026;5(2):e200307. Published 2026 Apr 22. doi:10.1212/NE9.0000000000200307
-
In part two of this series, Dr. Stacey Clardy and Dr. John Ney discuss the primary limitation of using claims data to estimate wait times for neurology services, particularly in rural areas or for subspecialty neurology care.
Show citation:
Laffargue EK, Van Der Goes DN, Wilson AM, Parziale SD, Sico JJ, Ney J. Neurology Wait Times After Primary Care or Emergency Department Visits Among the Commercially Insured Population in the United States: 2019-2023. Neurology. 2026;106(10):e218008. doi:10.1212/WNL.0000000000218008
-
In part two of this series, Dr. Stacey Clardy and Dr. John Ney discuss the primary limitation of using claims data to estimate wait times for neurology services, particularly in rural areas or for subspecialty neurology care.
Show citation:
Laffargue EK, Van Der Goes DN, Wilson AM, Parziale SD, Sico JJ, Ney J. Neurology Wait Times After Primary Care or Emergency Department Visits Among the Commercially Insured Population in the United States: 2019-2023. Neurology. 2026;106(10):e218008. doi:10.1212/WNL.0000000000218008
-
In part one of this two-part series, Dr. Jeff Ratliff and Dr. Gabriela Figueiredo Pucci shares the most important takeaway about professional identity formation among those actively engaged in neurology communities on social media.
Show citation:
Pucci GF, Gheihman G, Albin CSW. Education Research: A Qualitative Analysis of the Role of Social Media in Neurology Trainees' Professional Identity Formation. Neurol Educ. 2026;5(2):e200307. Published 2026 Apr 22. doi:10.1212/NE9.0000000000200307
-
In part one of this series, Dr. Stacey Clardy and Dr. John Ney break down the difference between mean and median wait times for new neurology appointments.
Show citation:
Laffargue EK, Van Der Goes DN, Wilson AM, Parziale SD, Sico JJ, Ney J. Neurology Wait Times After Primary Care or Emergency Department Visits Among the Commercially Insured Population in the United States: 2019-2023. Neurology. 2026;106(10):e218008. doi:10.1212/WNL.0000000000218008
-
Dr. Gillian L. Gordon Perue discusses asundexian and the OCEANIC-STROKE trial.
Show citation:
Sharma M, Dong Q, Hirano T, et al. Asundexian for Secondary Stroke Prevention. N Engl J Med. 2026;394(15):1467-1479. doi:10.1056/NEJMoa2513880
-
Dr. Madeline Russell discusses a common complication faced by patients with acute ischemic stroke.
Show citation:
Schwarz G, Cascio Rizzo A, Ambler G, et al. Contrast-Associated Acute Kidney Injury After Thrombectomy for Ischemic Stroke: Prognostic Impact and CAN-REST Predictive Score. Neurology. 2026;106(6):e214655. doi:10.1212/WNL.0000000000214655
-
Dr. Bradley Ong discusses the use of eptinezumab in combination with patient education is an effective treatment for reducing disease burden in patients living with chronic migraine complicated by medication overuse.
Show citation:
Jensen RH, Lundqvist C, Schytz HW, et al. Eptinezumab With Patient Education for Chronic Migraine and Medication-Overuse Headache: The Randomized, Placebo-Controlled RESOLUTION Trial. Neurology. 2026;106(8):e214863. doi:10.1212/WNL.0000000000214863
-
Dr. Shuvro Roy and Dr. Amanda Piquet discuss a brief overview of stiff person syndrome, as well as the trial and the trial results.
Read more about this abstract on the AAN website.
Show transcript:
Dr. Shuvro Roy:
Hi, this is Shuvro Roy from the University of Washington and welcome to today's Neurology Minute. I just wrapped a longer conversation with Amanda Piquet from the University of Colorado Anschutz School of Medicine. We were just talking about the recent Phase 2 trial evaluating Miv-cel Kyverna Therapeutics' anti-CD19 CAR T-cell therapy in patients with Stiff Person Syndrome. Amanda, would you mind taking us through a brief overview of SPS as well as the trial and their trial results?
Dr. Amanda Piquet:
So Stiff Person Syndrome, or SPS, is a rare disabling autoimmune neurologic disease with a major unmet need. About 80% of patients ultimately lose their mobility and we currently have no FDA approved therapies. Existing treatments like IVIG, rituximab, and plasmapheresis are all used off label, often requiring chronic dosing and frequently failing to stop progression. KYSA-8 is a registrational Phase 2 study of 26 patients with refractory SPS. Patients experienced rapid, statistically significant and clinically meaningful improvement across all primary and secondary endpoints. Primary endpoint was the timed 25-foot walk. And this improved by a median of 46% at 16 weeks. Of patients requiring walking aids at baseline, about two thirds no longer needed them by week 16 to complete that 25-foot walk. Some patients who had struggled to walk were even able to run again after treatment.
Another key finding was that all patients discontinued chronic immune therapies and remained off treatment as of the last follow-up. From a safety standpoint, miv-cel was generally well tolerated, with no high grade CRS or ICANS observed. In my opinion, these outcomes are unlike anything we've seen previously with Stiff Person Syndrome and may represent a paradigm shift, not only for SPS, but potentially for other antibody-mediated neurologic diseases more broadly.
Dr. Shuvro Roy:
Just curious, are there any upcoming implications for the application of this treatment for patients, you think, in the coming year or so?
Dr. Amanda Piquet:
Kyverna, the company who developed miv-cel, has initiated a rolling BLA with the FDA for potential approval and this would be, if approved, the first CAR-T therapy for SPS. So we're anxiously awaiting the outcome of that process.
Dr. Shuvro Roy:
Fantastic. Amanda, thank you so much for your time. And if you are intrigued and want to know more details behind the findings in the study as well as a conversation around CAR-T therapy for autoimmune neurologic disease as a whole, I encourage you to check out the Neurology Podcast feed for our full conversation there. Thanks for tuning in.
-
Dr. Shuvro Roy and Dr. Amanda Piquet discuss a brief overview of stiff person syndrome, as well as the trial and the trial results.
Read more about this abstract on the AAN website.
Show transcript:
Dr. Shuvro Roy:
Hi, this is Shuvro Roy from the University of Washington and welcome to today's Neurology Minute. I just wrapped a longer conversation with Amanda Piquet from the University of Colorado Anschutz School of Medicine. We were just talking about the recent Phase 2 trial evaluating Miv-cel Kyverna Therapeutics' anti-CD19 CAR T-cell therapy in patients with Stiff Person Syndrome. Amanda, would you mind taking us through a brief overview of SPS as well as the trial and their trial results?
Dr. Amanda Piquet:
So Stiff Person Syndrome, or SPS, is a rare disabling autoimmune neurologic disease with a major unmet need. About 80% of patients ultimately lose their mobility and we currently have no FDA approved therapies. Existing treatments like IVIG, rituximab, and plasmapheresis are all used off label, often requiring chronic dosing and frequently failing to stop progression. KYSA-8 is a registrational Phase 2 study of 26 patients with refractory SPS. Patients experienced rapid, statistically significant and clinically meaningful improvement across all primary and secondary endpoints. Primary endpoint was the timed 25-foot walk. And this improved by a median of 46% at 16 weeks. Of patients requiring walking aids at baseline, about two thirds no longer needed them by week 16 to complete that 25-foot walk. Some patients who had struggled to walk were even able to run again after treatment.
Another key finding was that all patients discontinued chronic immune therapies and remained off treatment as of the last follow-up. From a safety standpoint, miv-cel was generally well tolerated, with no high grade CRS or ICANS observed. In my opinion, these outcomes are unlike anything we've seen previously with Stiff Person Syndrome and may represent a paradigm shift, not only for SPS, but potentially for other antibody-mediated neurologic diseases more broadly.
Dr. Shuvro Roy:
Just curious, are there any upcoming implications for the application of this treatment for patients, you think, in the coming year or so?
Dr. Amanda Piquet:
Kyverna, the company who developed miv-cel, has initiated a rolling BLA with the FDA for potential approval and this would be, if approved, the first CAR-T therapy for SPS. So we're anxiously awaiting the outcome of that process.
Dr. Shuvro Roy:
Fantastic. Amanda, thank you so much for your time. And if you are intrigued and want to know more details behind the findings in the study as well as a conversation around CAR-T therapy for autoimmune neurologic disease as a whole, I encourage you to check out the Neurology Podcast feed for our full conversation there. Thanks for tuning in.
- Visa fler
